See what’s happening at FerGene
New Analysis of Phase 3 study presented at SUO 2020
New Data Analyses from Phase 3 Study of Investigational Gene Therapy Nadofaragene Firadenovec...
FerGene announces Landmark Phase 3 study published in The Lancet Oncology
Landmark Study in Non-Muscle Invasive Bladder Cancer Evaluating Breakthrough Investigational Gene...
FerGene Provides Update on BLA for Nadofaragene Firadenovec
The U.S. Food and Drug Administration (FDA) has issued a response to the Biologics License...
FerGene to present bladder cancer data at 2020 ASCO Genitourinary Cancers Symposium
Data highlight a need for bladder-sparing therapies to improve outcomes for patients with...
FerGene Appoints David Meek Chief Executive Office
CAMBRIDGE, Mass. - December 19, 2019 FerGene, a new gene therapy company launched by Ferring...
FerGene announces pivotal Phase 3 study of nadofaragene firadenovec met its primary endpoint with more than half of patients with high-grade non-muscle invasive bladder cancer (CIS ± Ta/T1) achieving a complete response at three months
The multi-center study met its primary endpoint with 53% of CIS ± Ta/T1 patients achieving a...
Ferring and Blackstone Life Sciences invest over $570 million USD in novel investigational gene therapy for bladder cancer patients
Ferring launches new company FerGene, with a focus on the global development and US...
